Apimeds Pharmaceuticals US, Inc.
APUSNYSE
$0.66
↑ +0.8%Jul 17 close · end-of-day
Price
1Y↓ -96.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$10.2M
Enterprise Value
$7.8M
P/E
—
P/S
—
P/B
0.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$40.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-32.1%
ROIC
-15.1%
Debt / Equity
—
Net Cash
$2.5M
Return 1Y
-96.3%
Company profile
We are a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. We are located at 2 East Broad Street, 2nd Floor, Hopewell, New Jersey.
- CEO
- Erik C. Emerson
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 2
- Headquarters
- New Jersey
- Website
- www.apimedsus.com
Earnings
APUS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$2.26↑ +4420.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$747,436.00 | -$1.3M | -$11.9M |
| Net income | -$777,694.00 | -$1.4M | -$6.0M |
| Diluted EPS | -$0.17 | -$0.18 | -$0.55 |
| Operating cash flow | -$627,790.00 | -$733,526.00 | -$8.9M |
| Free cash flow | — | — | -$9.0M |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$427,757.00 | -$299,999.00 | -$275,613.00 | -$364,368.00 | -$2.7M | -$1.8M | -$7.0M | -$12.2M |
| Net income | -$449,363.00 | -$332,521.00 | -$311,633.00 | -$402,397.00 | -$2.7M | -$1.8M | -$1.2M | -$35.1M |
| Diluted EPS | -$0.06 | -$0.04 | -$0.04 | -$0.05 | -$0.26 | -$0.14 | -$0.10 | -$2.26 |
| Operating cash flow | -$184,055.00 | -$186,755.00 | -$99,616.00 | -$20,313.00 | -$3.4M | -$1.7M | -$3.8M | -$2.1M |
| Free cash flow | — | — | — | — | — | -$1.7M | — | -$2.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.